of heart failure with reduced ejection fraction. Entresto is indicated to reduce the risk of
cardiovascular death and heart failure hospitalization.
Furthermore, robust pipeline of drugs over the forecast period (2018-2026), is another factor driving
growth of acute heart failure therapeutics market. For instance, in March 2017, Cardioxyl
Pharmaceuticals’ CXL-1427: a novel nitroxyl (HNO) donor (prodrug), which now operates under
the Bristol-Myers Squibb Company (after Cardioxyl Pharmaceuticals’ acquisition by Bristol-Myers
Squibb in December 2015); is present in Phase 2 clinical development phase. CXL-1427 is
indicated to use as an intravenous treatment for acute decompensated heart failure (ADHF).
Successful completion and further launch of Bristol-Myers Squibb’s innovative drug in future, will
help to boost the acute heart failure (AHF) therapeutics market growth during the forecast period.
Various lifestyle factors are responsible to increase risk heart attack and stroke, which includes
smoking, overweight, eating foods with high fat and cholesterol, and physical inactivity.
Furthermore, patients suffering with heart failure are at high risk to one or more conditions such as
coronary artery disease, myocardial infraction, high blood pressure or hypertension, abnormal heart
valves, dilated cardiomyopathy, hypertrophic cardiomyopathy, severe lung disease, obesity, and
sleep apnea, among others. For instance, according to the World Health Organization (WHO),
October 2017 data findings, in 2016, over 1.9 billion adults, were overweight, worldwide. Among
which over 650 million were obese. Moreover, according to the same source, raised BMI index,
owing to overweight and obesity are the major risk factors for cardiovascular disease, which was
the leading cause of death in 2012, worldwide.
Acute Heart Failure (AHF) Therapeutics Market Restraints
Acute heart failure is a common condition associated with considerable morbidity, mortality, and
cost. However, evidence-based data on treating heart failure in the acute setting are limited, and
current individual treatment options have variable efficacy. Furthermore, healthcare team often need
to customize patient care in acute heart failure treatment. For instance, dyspnea is the most common
symptom associated with AHF patients. However, this symptom is non-specific as other medical
conditions are commonly associated with dyspnea, including pneumonia, exacerbations of chronic
obstructive pulmonary disease, pulmonary embolism, acute coronary syndrome, and asthma. This is
another factor negatively affecting growth of the acute heart failure (AHF) therapeutics market.
Acute Heart Failure (AHF) Therapeutics Market – Regional Analysis
Geographically, the market is segmented into North America, Latin America, Europe, Middle East,
Asia Pacific, and Africa. North America is expected to hold dominant position in global acute heart
failure (AHF) therapeutics market, due to high prevalence of acute heart failure cases, in this region.
For instance, according to Centers for Disease Control and Prevention (CDC), June 2016, around
5.7 million adults in the U.S. suffered from heart failure, in 2016. Moreover, about half of the
people who develop heart failure die within 5 years of diagnosis.
Furthermore, growing prevalence of obesity have increased risk of developing acute heart failure
(AHF). According to CDC, May 2017 data findings, between 2013 and 2014, 37.9% of adults aged
20 years and over were obese, in the U.S. Therefore, high prevalence of risk factors and acute heart
failure (AHF) cases in these region are expected to drive growth of this market over the forecast
period.
Asia Pacific acute heart failure (AHF) therapeutics market is projected to witness significant
growth, due to increasing focus of healthcare organizations in creating awareness regarding
increasing risk factors of acute heart failure. For instance, in June 2016, Fortis Hospital, India
launched Fortis Heart Rhythm and Heart failure Centre in Bangalore, to increase awareness among
people regarding heart failure, stroke, and various other cardiovascular disease.